Dukagjin Blakaj | Radiation Oncology | Best Researcher Award

Published on by Cell Biologist

Prof. Dukagjin Blakaj | Radiation Oncology | Best Researcher Award

Prof. Dukagjin Blakaj, The Ohio State University, United States

Dr. Dukagjin M. Blakaj, MD, PhD, is a distinguished physician-scientist and academic leader in radiation oncology, specializing in proton therapy. Currently serving as the Vice Chair of Clinical Operations and holding the prestigious Drs. Malati and Ganesh Potdar Endowed Professorship at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital, he brings visionary leadership in patient-centered oncology care. With dual degrees in medicine and biochemistry, Dr. Blakaj integrates clinical expertise with advanced translational research. He is renowned for developing innovative radiotherapy protocols, advancing artificial intelligence applications in oncology, and mentoring future clinician-scientists. His work significantly influences treatment outcomes for head and neck cancers, including HPV-related oropharyngeal cancer, and is published in top-tier journals. A respected thought leader and collaborative partner, Dr. Blakaj embodies excellence in academic medicine, multidisciplinary team leadership, and compassionate patient care.

Publication Profile: 

Google Scholar

Scopus

Orcid

Education:

Dr. Blakaj’s educational path is both extensive and interdisciplinary. He earned his MD, PhD, and MS in Biochemistry from the Albert Einstein College of Medicine in New York, where he focused on molecular interactions in biological systems. Before that, he completed both a BA in Chemistry and Molecular Biology & Biophysics and an MA in Chemistry from Wesleyan University in Middletown, CT. His doctoral work explored protein-RNA interactions, laying the groundwork for his scientific rigor and precision. This strong biochemical foundation supports his innovative clinical research in radiation oncology and immunotherapy. His education highlights a consistent pattern of academic excellence and intellectual curiosity, equipping him with a rare blend of clinical insight and research acumen that continues to impact cancer treatment paradigms worldwide.

Professional Experience:

Dr. Dukagjin Blakaj is the Vice Chair of Clinical Operations in Radiation Oncology and Drs. Malati and Ganesh Potdar Endowed Professor in Proton Therapy at OSUCCC – James Cancer Hospital. As a senior faculty member, he has led transformative improvements in clinical care, quality assurance, and translational oncology research. His multidisciplinary collaboration extends across surgery, radiology, oncology, and data science, driving innovations such as AI-guided treatment protocols and digital health integration. Dr. Blakaj has also played a critical role in operationalizing proton therapy and implementing personalized cancer therapies. His background spans high-impact clinical trials, program development, and mentorship. The combination of clinical leadership and academic scholarship positions him as a strategic thinker with practical, evidence-driven execution. His commitment to precision medicine and patient-centered care distinguishes him among modern radiation oncologists.

Awards and Honors:

Dr. Blakaj has received numerous accolades that reflect his clinical excellence, research innovation, and service to the academic community. Notably, he was awarded the Drs. Malati and Ganesh Potdar Endowed Professorship in Radiation Oncology – Proton Therapy (effective June 2025), the highest honor granted by Ohio State University. His ABR Volunteer Service Award (July 2025) highlights his contributions to professional standards and education. He was selected for the James Outstanding Physician Peer Award for exemplary leadership, professionalism, and collaboration (August 2024). Additionally, his abstract ranked in the Top 7 of 146 presentations at ACRO, underscoring his research’s national impact. Dr. Blakaj’s consistent recognition across service, research, and teaching is a testament to his dedication, integrity, and influence in the field of oncology.

Research Focus:

Dr. Blakaj’s research is centered on optimizing cancer treatment outcomes through precision radiation therapy, immunotherapy integration, and the application of artificial intelligence in oncology. He focuses primarily on head and neck cancers, with additional emphasis on HPV-associated oropharyngeal carcinoma, FLASH radiotherapy, and treatment response prediction using circulating tumor DNA and inflammatory indices. He co-leads interdisciplinary studies leveraging machine learning, big data, and digital health tools to personalize care and reduce treatment toxicity. His research is both translational and clinically grounded, often influencing national clinical practice guidelines and multi-center trials. As a key contributor to high-impact publications, Dr. Blakaj has established himself as a thought leader in adaptive radiotherapy and survivorship outcomes. His pioneering work in proton therapy protocols and patient-reported outcomes continues to bridge the gap between innovative science and practical oncology care.

Publications Top Notes: 

  1. An integrated ML-based prognostic model in head and neck cancer using inflammatory markers and financial toxicity

  2. Vertebral endplate disruption and compression fracture risk: Expanded radiotherapy analysis

  3. Nasopharyngeal carcinoma in nonendemic regions: Characteristics and treatment outcomes

  4. Emerging paradigms in radiation oncology: Evolution and patient-centric care

  5. FLASH radiotherapy: From in vivo data to clinical translation

  6. Digital health tools in radiation oncology: Development and implementation review

  7. ctDNA as a response marker in HPV-associated oropharyngeal carcinoma: A pilot study

  8. AI, machine learning, and big data in radiation oncology

  9. Predicting cisplatin tolerability in elderly head and neck cancer patients

  10.  Tobacco, marijuana, and alcohol use impact on survival in metastatic head and neck cancer

Conclusion:

Dr. Dukagjin M. Blakaj is a highly qualified, forward-thinking researcher whose body of work exemplifies excellence in translational oncology. He brings together advanced clinical practice, cutting-edge research, and visionary leadership to improve cancer care outcomes and drive future innovations in radiation therapy.

Given his sustained productivity, multidisciplinary leadership, and contributions to patient-centered care models, Dr. Blakaj is a deserving and outstanding nominee for the Best Researcher Award.

Sukanta Nath | Cancer Research | Distinguished Scientist Award

Published on by Cell Biologist

Dr. Sukanta Nath | Cancer Research | Distinguished Scientist Award

Dr. Sukanta Nath, Atal Bihari Vajpayee Regional Cancer Centre, India

Dr. Sukanta Nath is a dedicated Research Scientist with over 13 years of experience in molecular biology, virology, and cancer research. He currently serves at the Atal Bihari Vajpayee Regional Cancer Centre, Agartala, Tripura, where he has led several impactful studies in oral cancer patient care. Holding a Ph.D. in Biotechnology from Gauhati University, Dr. Nath has consistently demonstrated excellence in scientific inquiry, especially in clinical intervention studies. His collaborative works with clinical and academic experts have produced over 10 peer-reviewed publications in reputed journals. Dr. Nath’s research emphasizes evidence-based nursing practices, molecular diagnostics, and the improvement of post-surgical outcomes in cancer patients. Known for his commitment to translational research, Dr. Nath is playing a pivotal role in bridging molecular science with patient-centered care in North-East India. His multidimensional expertise and scholarly contributions make him a deserving candidate for recognition as a Distinguished Scientist.

Publication Profile: 

Scopus

Strengths for the Award:

  1. Extensive Research Experience:
    With over 13 years of hands-on experience in molecular biology, cancer research, and virology, Dr. Nath has a well-established research career that aligns with the award’s standards.

  2. Focused Contributions to Cancer Research:
    His work at Atal Bihari Vajpayee Regional Cancer Centre has significantly contributed to oral cancer patient management, particularly through randomized intervention studies improving postoperative recovery and mental health.

  3. High Research Output:
    He has authored or co-authored 10+ peer-reviewed publications, many of which focus on novel and under-explored aspects such as nursing intervention in cancer care—a progressive and human-centered approach.

  4. Multidisciplinary Approach:
    Dr. Nath bridges molecular diagnostics, clinical research, and public health, evident in his work on HPV molecular epidemiology and AML treatment reviews.

  5. Collaborative and Institutional Impact:
    His collaborations with clinicians, nurses, and academic institutions highlight his team-oriented and translational research vision, helping integrate academic outputs into real-world healthcare.

Areas for Improvement:

  1. International Exposure:
    Dr. Nath could enhance his academic profile with international fellowships, collaborative projects, or presentations at global conferences, which would add broader recognition and perspective to his impactful regional work.

  2. Grant Acquisition & Leadership Roles:
    Documented principal investigator roles or research funding/grant awards would strengthen his leadership credentials in scientific research.

  3. Recognition & Awards:
    While he has a commendable publication record, more national or state-level recognitions, fellowships, or memberships in professional bodies (like ICMR, DBT, etc.) would boost his candidacy for national-level honors.

Education:

Dr. Sukanta Nath’s academic foundation is rooted in the biological sciences, beginning with a B.Sc. in Botany, Zoology, and Physiology from Calcutta University (2003, First Class). He went on to complete his M.Sc. in Biotechnology from Utkal University in 2006, securing First Class (67%). His research potential culminated in a Ph.D. in Biotechnology from Gauhati University, awarded in 2018, where he specialized in molecular biology and translational biomedical science. His education reflects a progressive mastery of theoretical and applied biotechnology, allowing him to engage in complex interdisciplinary research. Despite modest early academic challenges in higher secondary and matriculation, Dr. Nath’s academic trajectory sharply ascended, reflecting perseverance and intellectual growth. His doctoral training equipped him with specialized skills in molecular diagnostics, research design, and bioanalytical tools, which now form the backbone of his professional research work in cancer and infectious disease.

Professional Experience:

Dr. Nath is presently serving as a Research Scientist at the Atal Bihari Vajpayee Regional Cancer Centre, Tripura, since April 2020, where he conducts pivotal research on postoperative outcomes and interventions in oral cancer patients. Previously, he worked as a Research Associate at the College of Fisheries, Central Agricultural University, Tripura (2018–2019), contributing to institutional-level biotech projects. In 2017–2018, he served as a Molecular Scientist and Quality Manager at Agility Diagnostics Pvt. Ltd., Delhi, a NABL-accredited molecular diagnostics lab, where he gained valuable experience in molecular testing and lab quality control. With over 13 years of interdisciplinary experience, Dr. Nath has successfully combined clinical and molecular biology expertise, making impactful contributions to oncology, diagnostics, and public health. His adaptability across academic, clinical, and industry environments illustrates his wide-ranging capabilities as a biomedical researcher and project leader.

Awards and Honors:

While specific named awards are not listed in the provided resume, Dr. Sukanta Nath’s contributions have earned peer recognition through frequent lead and co-author roles in high-impact publications. His ongoing collaboration with clinicians, epidemiologists, and nursing researchers has positioned him as a sought-after expert in cancer-related intervention studies in North-East India. He has been an instrumental figure in pioneering randomized clinical studies assessing fatigue, anxiety, and quality of life in post-surgical oral cancer patients—work that has been accepted in internationally indexed journals. His contributions to the molecular epidemiology of HPV in Indian women also reflect national relevance. The volume and scope of his work, alongside a sustained publication record, underline a distinguished career in translational cancer research. Nomination for the Distinguished Scientist Award is a well-aligned recognition of his achievements and continued potential to contribute at the national level.

Research Focus:

Dr. Nath’s primary research interest lies in molecular biology, oncology, and virology, with a strong emphasis on translational studies that impact patient care. He has led intervention-based research evaluating the role of nursing and clinical protocols in improving postoperative recovery among oral cancer patients. His work assesses anxiety, fatigue, and quality of life post-surgery using evidence-based methodologies. Dr. Nath has also contributed significantly to molecular epidemiology, particularly studying the distribution of high-risk HPV genotypes among women in North-East India. His experience in diagnostics and biotech allows him to approach clinical problems from both biomedical and molecular perspectives, making his research integrative and impactful. The focus on nursing intervention studies, rarely explored in Indian cancer centers, demonstrates his commitment to holistic cancer care. His future goals involve scaling such studies to wider patient populations and contributing to national cancer care protocols.

Publications Top Notes:

  1. 📘 Effectiveness of a supportive educational intervention on pain and physical function among patients undergone abdominal surgery: A randomized controlled trial

  2. 📗 Effectiveness of comprehensive nursing intervention on alleviating postoperative fatigue and anxiety in patients with oral cancer

  3. 📕 Molecular epidemiology and genotype distribution of genital high-risk human papillomavirus among women in North–East India

  4. 📙 Effectiveness of Nursing Interventions on Anxiety among Postoperative Oral Cancer Patients in Regional Cancer Centre, Tripura

  5. 📒 Importance of Nursing Intervention in Alleviating Post-Surgical Fatigue for Patients with Oral Cancer

  6. 📓 Does comprehensive nursing intervention improve post-surgical anxiety in patients with oral cancer?

  7. 📔 Post-Surgical Evaluation of Quality of Life in Patients with Oral Cancer: An Intervention Study from India

  8. 📚 Assessment of Fatigue and Quality of Life amongst Post-Operative Oral Cancer Patients: A Randomized Case Control Study

  9. 📙 Effect of Comprehensive Nursing Intervention on Anxiety and Quality of Life in Postoperative Patients with Oral Cancer

  10. 📗 Prognosis and Treatment in Acute Myeloid Leukemia: A Comprehensive Review

Conclusion:

Dr. Sukanta Nath has demonstrated dedicated service, innovative research, and strong scientific output in the fields of molecular biology and oncology, particularly with a patient-centric approach to oral cancer care. His work addresses a critical healthcare challenge in North-East India and proposes practical solutions backed by rigorous research methodologies.

 

Mohammad reza Atashzar | Cancer stem cell | Best Researcher Award

Published on by Cell Biologist

Dr. Mohammad reza Atashzar | Cancer stem cell | Best Researcher Award

Dr. Mohammad reza Atashzar, Dep of immunology, Fasa university of medical sciences ( FUMS ), Iran

Dr. Mohammad Reza Atashzar is an Assistant Professor in the Department of Immunology at Fasa University of Medical Sciences (FUMS), Iran. With an enduring passion for tumor immunology, stem cells, vaccine design, and immunotherapy, he has made significant contributions through both basic and translational research. Dr. Atashzar earned his PhD in Immunology from Shahid Beheshti University of Medical Sciences and has since engaged in teaching, mentoring, and publishing extensively in high-impact journals such as The Lancet Oncology, Frontiers in Immunology, and Current Molecular Medicine. His innovative research spans exosome-based therapy, cancer biomarkers, cytokine profiling, and radiogenomics. Dr. Atashzar has also contributed to international collaborations across Germany, Finland, and the UK, showcasing a global outlook in biomedical science. An awardee of the KAI 2022 International Travel Grant and recognized as the Top Researcher at FUMS in 2021, he remains deeply committed to advancing immunological sciences for clinical and therapeutic benefit.

Publication Profile: 

Orcid

Google Scholar

✅ Strengths for the Award:

  1. Extensive Research Contributions
    Dr. Atashzar has authored numerous peer-reviewed publications in reputable journals including The Lancet Oncology, Frontiers in Immunology, Current Molecular Medicine, and Computers in Biology and Medicine. His work spans critical fields like cancer immunology, exosome therapy, stem cell immunomodulation, and vaccine research.

  2. High-Impact Publications
    Several of his papers have significant citation counts—556 for Frontiers in Immunology, 284 for Journal of Cellular Physiology, and 207 for The Lancet Oncology, reflecting strong influence and relevance in the scientific community.

  3. International Recognition and Collaborations
    He has participated in international conferences (UK, China, Korea, Denmark, Spain, Italy) and collaborated with global institutions such as the University of Helsinki, University of Kiel, and GBD Collaborators, demonstrating a global research footprint.

  4. Innovation and Patents
    He has contributed to translational science through a published book on immunopharmacology and a pending patent for a microbiology loop sterilizer device, showing practical application of his research.

  5. Awards and Editorial Involvement
    Recognized with the International Travel Award (KAI 2022) and Top Researcher of FUMS (2021), and serving on editorial boards of scientific journals—further affirming his active role in academic development and peer review.

  6. Interdisciplinary Research Scope
    His research merges clinical immunology, oncology, AI-based prognostic tools, and cellular therapy, making his work not only innovative but also future-oriented.

⚠️ Areas for Improvement:

  1. Increase in First or Senior Author Publications
    While his contributions are numerous, strengthening his authorship role in key studies would amplify his recognition as a principal investigator.

  2. Patent Commercialization & Technology Transfer
    Moving from patent design to real-world implementation or licensing could significantly raise the translational value of his research.

  3. Higher Grant Involvement
    More participation in national/international grant-funded programs or consortiums would enhance the scale and visibility of his research.

  4. Focused Research Niche
    Narrowing focus slightly (e.g., prioritizing tumor immunology or exosome-based therapies) could help build a globally recognized brand in a specialized field.

🎓 Education:

Dr. Atashzar completed his undergraduate and master’s studies in Immunology at Shiraz University of Medical Sciences (SUMS), Shiraz, Iran. Building on his foundational expertise, he pursued his PhD in Immunology at Shahid Beheshti University of Medical Sciences, Tehran. His doctoral thesis—“Investigation of the Effects of B16F10 Derived Exosomes Enriched with miRNA-211 in Induction of Antitumor Response in the Mouse Model of Melanoma”—reflected his early interest in cancer immunotherapy and translational research. Throughout his academic journey, Dr. Atashzar displayed a strong inclination toward exploring novel immune pathways and cell-based therapies. His formal education has laid a robust foundation for his ongoing work in immunological sciences, particularly in relation to tumor microenvironment, cytokine profiling, exosomes, and vaccine innovation. He has also undertaken continuous learning through collaborations and international scientific conferences, allowing him to integrate cutting-edge methodologies into his research and teaching repertoire.

🧪 Professional Experience:

Dr. Mohammad Reza Atashzar currently serves as an Assistant Professor of Immunology at Fasa University of Medical Sciences, with additional teaching responsibilities at Larestan University of Medical Sciences. He has accumulated over a decade of experience in academic instruction and biomedical research. His research portfolio includes multiple funded projects, notably in cancer immunology, cytokine regulation, diabetes-related immune responses, and exosome-based therapeutics. Dr. Atashzar has worked closely with international teams in Germany, Finland, and the UK, facilitating interdisciplinary approaches and innovations in clinical immunology. He is an editorial board member for reputed journals such as The International Journal of Neuroscience and Journal of International Medical Research. In parallel, he actively contributes to conference presentations worldwide, covering topics from cancer stem cells to immune biomarkers. His hands-on laboratory experience, combined with a global research network, enables him to lead and mentor in advanced areas like CAR-T cell therapy and personalized immunotherapy.

🧬 Research Focus:

Dr. Atashzar’s research is centered on tumor immunology, exosome-based therapies, cancer stem cells, CAR-T cell technology, cytokine profiling, and immunopharmacology. He has a keen interest in how immune cells—particularly T cells, NK cells, and regulatory B cells—can be harnessed for cancer therapy. His notable projects have explored the immunomodulatory effects of miRNA-enriched exosomes, the role of TLR4 polymorphisms in diabetes, and cytokine alterations in addiction and radiation-exposed individuals. He is also pioneering in translational research areas such as vaccine design, radiogenomics, and bio-immune device development. Dr. Atashzar integrates bioinformatics and machine learning for predictive modeling, evident in his contributions to COVID-19 prognostic modeling using CT radiomics. His work is driven by the goal of personalized immunotherapy and the identification of novel biomarkers for cancer progression and immune regulation. Through interdisciplinary collaborations, he aims to bridge the gap between immunological research and clinical application.

📚 Publications Top Notes:

  1. 🧬 Cancer stem cells: A review from origin to therapeutic implications – Journal of Cellular Physiology

  2. 🧪 Tumor‐Derived Exosomes Enriched by miRNA‐211a Promote Antitumor Immune Response in B16F10 Tumor‐Bearing Mice – APMIS

  3. 🔬 The effects of tumor-derived exosomes enriched with miRNA-211a on B16F10 cells – Contemporary Oncology

  4. 💉 The effects of type 2 diabetes mellitus on organ metabolism and the immune system – Frontiers in Immunology

  5. 🧠 Pyrin and hematopoietic interferon-inducible nuclear protein domain proteins: innate immune sensors for cytosolic and nuclear DNA – Critical Reviews in Immunology

  6. 🧪 Reduced levels of T-helper 17-associated cytokines in serum of breast cancer patients – Central European Journal of Immunology

  7. 🧫 The Role of IL‐6, IL‐10 and CRP in Gastrointestinal Cancers – Cell Biology International

  8. 🌍 The global burden of adolescent and young adult cancer in 2019 – The Lancet Oncology

  9. 🖥️ COVID-19 prognostic modeling using CT radiomic features and ML algorithms – Computers in Biology and Medicine

  10. 🌡️ Mesenchymal stromal cells in bone marrow niche of multiple myeloma – Cancer Cell International

📌 Conclusion:

Dr. Mohammad Reza Atashzar is highly suitable for the Best Researcher Award. His body of work reflects a deep commitment to scientific advancement in cancer immunology, immunotherapy, and bio-innovation. He combines strong academic output with international engagement, cross-disciplinary impact, and teaching contributions. With growing influence in both research and translational domains, Dr. Atashzar is poised to further elevate biomedical research in Iran and globally.

Zu-Chian Chiang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Zu-Chian Chiang | Cancer Cell Biology | Best Researcher Award

Dr. Zu-Chian Chiang , Fujian Normal University , China

Dr. Zu-Chian Chiang is a highly accomplished postdoctoral fellow at the Biomedical Research Center of Southern China, Fujian Normal University, specializing in cancer research and regenerative medicine. With extensive experience in antibody-drug conjugates (ADCs), peptide synthesis, and tissue engineering, his work focuses on the development of targeted therapies and innovative biomaterials for medical applications. Dr. Chiang’s expertise includes both academic research and real-world clinical applications, and he has contributed to numerous peer-reviewed publications and conference presentations. Over the years, his research has received recognition from prestigious institutions such as the National Taiwan University and Academia Sinica. He also plays an active role in academic societies, providing his expertise as a peer reviewer for various scientific journals and as a key member of multiple international organizations. Dr. Chiang continues to make significant strides in biomedical engineering and cancer therapy.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Education and Experience:

    • Dr. Chiang has a robust academic background, with a Ph.D. in Materials and Chemical Engineering and an M.S. in Chemistry, both from reputable institutions in Taiwan. His postdoctoral experience spans multiple prestigious institutions, such as Academia Sinica and National Taiwan University Hospital, and his ongoing postdoc at the Biomedical Research Center of Southern China showcases his continued dedication to scientific progress.

  2. Research Excellence:

    • Dr. Chiang has made significant contributions to the field of cancer research, particularly in antibody-drug conjugates (ADCs), functional peptides for cancer research, and the development of specific aptamers as targeted therapies for cancer.

    • He has authored numerous high-quality peer-reviewed publications (with recent impactful papers), contributing to advancing understanding in immunotherapy, ADCs, and cancer therapeutics. His research has garnered attention in journals like Frontiers in Oncology and PLOS ONE.

  3. Awards and Recognition:

    • Dr. Chiang’s receipt of multiple prestigious awards, such as the 3rd Biotech Elite Training Reserve Program award, highlights his excellence in both academic and professional research. His achievements have earned recognition from both Taiwanese and Chinese scientific communities.

  4. Active Contribution to the Scientific Community:

    • Serving as a peer reviewer for the International Journal of Biological Macromolecules, as well as being involved in numerous scientific societies, demonstrates his commitment to advancing the field and his active engagement with the wider scientific community.

  5. Research Support and Funding:

    • Dr. Chiang has successfully secured research funding from prominent sources, such as the Department of Human Resources and Social Security, Fujian Province, showcasing his ability to lead and manage significant research projects. His ongoing research projects reflect a focus on cancer therapies and therapeutic advancements, further cementing his relevance in the field.

Areas for Improvement:

  1. Public Engagement and Outreach:

    • While Dr. Chiang has impressive research achievements, further expanding his presence in broader public engagement, such as science communication, could help make his findings accessible to a larger audience, especially in cancer therapy and regenerative medicine.

  2. Collaboration and Networking:

    • Dr. Chiang’s research has been highly productive, but future collaboration with other interdisciplinary teams could increase the breadth of his work and facilitate the development of novel, cross-disciplinary solutions.

  3. Increasing Citation Impact:

    • Although Dr. Chiang has 91 citations, his h-index of 5 suggests there may be room to increase the visibility and citation impact of his work. Strategic publishing in highly-cited journals or working with larger collaborative projects could elevate this metric.

  4. Mentorship and Training:

    • While his extensive postdoctoral training is impressive, Dr. Chiang’s experience in mentorship or leading research teams could be enhanced further. Serving as a mentor for students and junior researchers could help strengthen his leadership in the scientific community.

Education:

Dr. Zu-Chian Chiang earned his Ph.D. in Materials and Chemical Engineering from National United University, Taiwan (2008-2014), where he specialized in biomedical engineering under the mentorship of Professor An-Chong Chao and Dr. Guo-Chung Dong. Prior to that, he completed his M.S. in Chemistry from Tunghai University, Taiwan (2005-2007), under the guidance of Professor Feng-Di Lung. His doctoral research focused on creating innovative materials for biomedical applications, such as scaffolds for tissue engineering. Throughout his academic career, Dr. Chiang was awarded scholarships and fellowships recognizing his excellence in research, such as the First Outstanding Doctoral Scholarship at National United University and the Master’s Program Scholarship from the Hunan Fellow Association of Taiwan. His academic foundation laid the groundwork for his cutting-edge contributions to cancer research, drug delivery, and regenerative medicine, ensuring his continued impact in the field.

Experience:

Dr. Zu-Chian Chiang has accumulated a wealth of research experience, serving as a postdoctoral fellow at various prestigious institutions. Since September 2019, he has been working at the Biomedical Research Center of Southern China, Fujian Normal University, focusing on cancer therapies and advanced drug delivery systems. Prior to this, he held postdoctoral positions at the Institute of Biological Chemistry, Academia Sinica (2016-2019), and National Taiwan University Hospital’s Clinical Trial Center (2015-2016), where he worked on pioneering biotechnological projects, including the Taiwan Protein Project. Dr. Chiang’s expertise extends to developing antibody-drug conjugates (ADCs), functional peptides, and biomaterials for regenerative medicine. His involvement in various research groups has strengthened his interdisciplinary knowledge in both molecular and clinical aspects of cancer therapy. Dr. Chiang also gained valuable teaching experience while completing his degrees, serving as a teaching assistant in organic chemistry and chemical engineering courses throughout his academic career.

Awards and Honors:

Dr. Zu-Chian Chiang has received numerous prestigious awards throughout his career, reflecting his significant contributions to the field of biomedical research. Notable honors include the “Science and Technology Commissioner” title in Quanzhou, Fujian Province (2020), and the “Miaoli Southeastern Xindong Satellite Rotary Club Chairman Award” (2017). In 2016, he was honored as an awardee of the “3rd Biotech Elite Training Reserve Program” by National Taiwan University and Taiwan’s Ministry of Science and Technology. His academic achievements were further recognized with the Chung Hwa Rotary Annual Doctoral Program Award (2012), and he received the First Outstanding Doctoral Scholarship at National United University (2010). Additionally, Dr. Chiang was awarded the Master’s Program Scholarship from the Hunan Fellow Association of Taiwan (2007). These accolades reflect his outstanding dedication to scientific research, education, and professional development in the fields of cancer therapy and regenerative medicine.

Research Focus:

Dr. Zu-Chian Chiang’s primary research interests lie in the development of functional peptides for cancer therapy and tissue engineering, as well as the design of advanced biomolecular materials for regenerative medicine. His work focuses on antibody-drug conjugates (ADCs), targeting specific cancer cells for more effective therapies. One of his key research areas is developing specific aptamers as blockers, agonists, or antagonists for cancer treatment, aiming to enhance therapeutic outcomes. He is also dedicated to the synthesis of peptides that can aid in the regeneration of bone tissue and the creation of biomaterials that combine bioactive molecules for regenerative medicine. Through his research, Dr. Chiang aims to improve cancer treatments by targeting tumors more precisely, reduce side effects, and contribute to breakthroughs in drug delivery. His work also explores innovative methods of using biomaterials for enhancing regenerative medicine, thus bridging the gap between basic science and clinical application.

Publications Top Notes:

  1. “Generation and characterization of 7DC-DM1: a non-cleavable CD47-targeting antibody-drug conjugates with antitumor effects” 🧬💉

  2. “Strengthening effect of thalidomide combined with anti-PD1 antibody on enhancing immunity for lung cancer therapy” 🫁💪

  3. “Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo” 🫀⚛️

  4. “Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells” 🧪🧫

  5. “Preparation and characterization of dexamethasone-immobilized chitosan scaffold” 💊🧵

  6. “Characterization of the morphology and hydrophilicity of chitosan/caffeic acid hybrid scaffolds” 🧫🌿

  7. “Preparation and characterization of caffeic acid grafted chitosan/CPTMS hybrid scaffolds” 🍄🔬

Conclusion:

Dr. Zu-Chian Chiang is a highly qualified and accomplished researcher, with a strong track record in cancer research and therapeutic innovation. His work in developing antibody-drug conjugates, functional peptides, and aptamers demonstrates great promise in transforming cancer therapy. His academic credentials, publications, awards, and research funding solidify his standing as a top candidate for the Best Researcher Award. Further expansion into public engagement, interdisciplinary collaborations, and mentorship could further enhance his contributions to the field and his overall impact. Therefore, Dr. Chiang is certainly a strong contender for the award, with potential for even greater influence moving forward.